Science and Medicine

Alzheimer’s Drug Candidate May Be First to Prevent Disease Progression

A new drug candidate may be the first capable of halting the devastating mental decline of Alzheimer's disease,

A new drug candidate may be the first capable of halting the devastating mental decline of Alzheimer’s disease, based on the findings of a study published in PLoS ONE.

When given to mice with Alzheimer’s, the drug, known as J147, improved memory and prevented brain damage caused by the disease. The new compound, developed by scientists at the Salk Institute for Biological Studies, could be tested for treatment of the disease in humans in the near future.

“J147 enhances memory in both normal and Alzheimer’s mice and also protects the brain from the loss of synaptic connections,” said David Schubert, the head of Salk’s Cellular Neurobiology Laboratory, whose team developed the new drug. “No drugs on the market for Alzheimer’s have both of these properties.”

Although it is yet unknown whether the compound will prove safe and effective in humans, the Salk researchers’ say their results suggest the drug may hold potential for treatment of people with Alzheimer’s.

As many as 5.4 million Americans suffer from Alzheimer’s, according to the National Institutes of Health. More than 16 million will have the disease by 2050, according to Alzheimer’s Association estimates, resulting in medical costs of more than $1 trillion per year.

The disease causes a steady, irreversible decline in brain function, erasing a person’s memory and ability to think clearly until they are unable to perform simple tasks such as eating and talking, and it is ultimately fatal. Alzheimer’s is linked to aging and typically appears after age 60, although a small percentage of families carry a genetic risk for earlier onset. Among the top 10 causes of death, Alzheimer’s is the only one without a way to prevent, cure or slow down disease progression.

Read more: Alzheimer’s Drug Candidate May Be First to Prevent Disease Progression

No comments
 

World’s First Super Predator Had Remarkable Vision

The metre-long super predator Anomalocaris. (Credit: Artist's impression by Katrina Kenny/University of Adelaide.)

South Australian Museum and University of Adelaide scientists working on fossils from Kangaroo Island have found eyes belonging to a giant 500 million-year-old marine predator that sat at the top of Earth's first food chain.

This story will be accompanied by an artist's impression of the super predator on the front cover of the December 8, 2011 issue of Nature.

Paleontologists have discovered exceptionally preserved fossil eyes of the top predator in the Cambrian ocean from more than 500 million years ago: the fearsome meter-long Anomalocaris.

The scientists show that the world's first apex predator had highly acute vision, rivaling or exceeding that of most living insects and crustaceans.

The international team behind this discovery includes two Adelaide researchers, Dr. Michael Lee (SA Museum and University of Adelaide—Environment Institute and School of Earth & Environmental Sciences) and Dr. Jim Jago (SA Museum and UniSA), and was led by Dr. John Paterson (University of New England).

Read more: World’s First Super Predator Had Remarkable Vision

No comments
   

Dream Sleep Soothes Painful Memories

While humans spend one-third of their lives sleeping, there is no scientific consensus on the function of sleep.

During the dream phase of sleep, the body’s stress chemistry shuts down, taking the edge off difficult memories. The finding may help explain why people with post-traumatic stress disorder suffer reoccurring nightmares.

“The dream stage of sleep, based on its unique neurochemical composition, provides us with a form of overnight therapy, a soothing balm that removes the sharp edges from the prior day’s emotional experiences,” said Matthew Walker, associate professor of psychology and neuroscience at the University of California, Berkeley.

For people with PTSD, such as war veterans, this overnight therapy may not work effectively, so when a “flashback is triggered by, say, a car backfiring, they relive the whole visceral experience once again because the emotion has not been properly stripped away from the memory during sleep.”

Published in Current Biology, the study offers some of the first insights into the emotional function of Rapid Eye Movement (REM) sleep, which typically takes up 20 percent of a healthy human’s sleeping hours. Previous brain studies indicate that sleep patterns are disrupted in people with mood disorders such as PTSD and depression.

While humans spend one-third of their lives sleeping, there is no scientific consensus on the function of sleep. The research unlocks many of the mysteries linking sleep to learning, memory, and mood regulation—and shows the importance of the REM dream state.

“During REM sleep, memories are being reactivated, put in perspective and connected and integrated, but in a state where stress neurochemicals are beneficially suppressed,” says lead author Els van der Helm, doctoral student in psychology.

For the study, 35 healthy young adults were divided into two groups and viewed 150 emotional images twice, 12 hours apart, while an MRI scanner measured brain activity.

Read more: Dream Sleep Soothes Painful Memories

No comments
   

Page 17 of 52